Hi,
We wanted to share some exciting news with you:
On 23 June 2026, NICE published final draft guidance, recommending teplizumab as a clinically and cost-effective treatment for the NHS to commission and marking a step change in how stage 2 type 1 diabetes is treated.
For the first time, eligible people who are 8 years and over with stage 2 type 1 diabetes will have access to a treatment that can delay the progression of their condition by an average of nearly three years before it reaches symptomatic stage, where they need insulin to survive. This could really help those who are identified as having early stage Type 1 diabetes.
This is an exciting development, and partners across the Diabetes community are working together now to develop the new services and treatment pathways needed to deliver this new treatment.
Teplizumab is an immunotherapy that can delay the onset of symptomatic type 1 diabetes in people who are in stage 2 of the condition. This stage is identified through autoantibody screening and means the immune system has already begun attacking insulin-producing cells, but a person does not yet need insulin therapy or show symptoms.
For more information about NICE’s announcement, please visit the links below:
If you would like to be involved in screening then visit the ELSA Study page HERE.
The ELSA Study is screening children (age 2-15) and young adults (age 16-17) for type 1 diabetes. Children and young adults can have a simple finger stick blood test to find out their risk of developing type 1 diabetes in the future. This study is currently open to families living in England, Scotland, Wales and Northern Ireland.
Many thanks from all at Team DB : )
25 June 2026